ImmunoPrecise Antibodies Ltd. (IPA)
USD 0.46
(-0.71%)
USD 0.46
(-0.71%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 25.81 Million CAD | -35.11% |
| 2022 | 39.78 Million CAD | 46.51% |
| 2021 | 27.15 Million CAD | 72.79% |
| 2020 | 15.71 Million CAD | 30.08% |
| 2019 | 12.08 Million CAD | 4.87% |
| 2018 | 11.51 Million CAD | 59.74% |
| 2017 | 7.21 Million CAD | -8.02% |
| 2016 | 7.84 Million CAD | 371.99% |
| 2015 | 1.66 Million CAD | 2421.76% |
| 2014 | 65.87 Thousand CAD | -32.39% |
| 2013 | 97.43 Thousand CAD | 20.04% |
| 2012 | 81.16 Thousand CAD | -60.92% |
| 2011 | 207.71 Thousand CAD | -20.54% |
| 2010 | 261.41 Thousand CAD | -2.69% |
| 2009 | 268.62 Thousand CAD | 480.79% |
| 2008 | -70.54 Thousand CAD | -111.46% |
| 2007 | 615.63 Thousand CAD | 159.38% |
| 2006 | 237.35 Thousand CAD | 15.47% |
| 2005 | 205.54 Thousand CAD | 2.71% |
| 2004 | 200.11 Thousand CAD | -35.15% |
| 2003 | 308.59 Thousand CAD | 95.61% |
| 2002 | 157.75 Thousand CAD | -18.81% |
| 2001 | 194.3 Thousand CAD | 30.48% |
| 2000 | 148.91 Thousand CAD | -19.03% |
| 1999 | 183.9 Thousand CAD | -20.68% |
| 1998 | 231.83 Thousand CAD | -16.85% |
| 1997 | 278.81 Thousand CAD | 22.22% |
| 1996 | 228.13 Thousand CAD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 6.98 Million CAD | 30.18% |
| 2023 Q3 | 6.53 Million CAD | 9.66% |
| 2023 Q1 | 12.22 Million CAD | 30.18% |
| 2023 FY | 25.81 Million CAD | -35.11% |
| 2023 Q4 | 6.62 Million CAD | 1.33% |
| 2023 Q2 | 5.96 Million CAD | -51.24% |
| 2022 Q4 | 9.39 Million CAD | 24.83% |
| 2022 Q3 | 7.52 Million CAD | -28.96% |
| 2022 FY | 39.78 Million CAD | 46.51% |
| 2022 Q1 | 12.22 Million CAD | 63.58% |
| 2022 Q2 | 10.58 Million CAD | -13.38% |
| 2021 Q1 | 5.88 Million CAD | 12.11% |
| 2021 Q4 | 7.47 Million CAD | 12.51% |
| 2021 Q3 | 6.64 Million CAD | -7.2% |
| 2021 Q2 | 7.15 Million CAD | 21.7% |
| 2021 FY | 27.15 Million CAD | 72.79% |
| 2020 Q3 | 4.51 Million CAD | 30.96% |
| 2020 Q2 | 3.44 Million CAD | 37.82% |
| 2020 Q1 | 2.5 Million CAD | -24.88% |
| 2020 FY | 15.71 Million CAD | 30.08% |
| 2020 Q4 | 5.24 Million CAD | 16.13% |
| 2019 FY | 12.08 Million CAD | 4.87% |
| 2019 Q4 | 3.33 Million CAD | 37.59% |
| 2019 Q3 | 2.42 Million CAD | -30.46% |
| 2019 Q1 | 2.84 Million CAD | -28.68% |
| 2019 Q2 | 3.48 Million CAD | 22.33% |
| 2018 Q2 | 2.53 Million CAD | -3.87% |
| 2018 FY | 11.51 Million CAD | 59.74% |
| 2018 Q1 | 2.64 Million CAD | -4.33% |
| 2018 Q3 | 2.4 Million CAD | -5.37% |
| 2018 Q4 | 3.99 Million CAD | 66.16% |
| 2017 Q2 | 1.33 Million CAD | -7.5% |
| 2017 FY | 7.21 Million CAD | -8.02% |
| 2017 Q3 | 2 Million CAD | 49.81% |
| 2017 Q4 | 2.75 Million CAD | 37.74% |
| 2017 Q1 | 1.44 Million CAD | -13.25% |
| 2016 Q4 | 1.66 Million CAD | -66.29% |
| 2016 Q3 | 4.94 Million CAD | 1880.51% |
| 2016 Q2 | 249.62 Thousand CAD | -54.84% |
| 2016 Q1 | 552.73 Thousand CAD | 12917.88% |
| 2016 FY | 7.84 Million CAD | 371.99% |
| 2015 FY | 1.66 Million CAD | 2421.76% |
| 2015 Q1 | 5202.00 CAD | -40.32% |
| 2015 Q2 | 2940.00 CAD | -43.48% |
| 2015 Q3 | 14.93 Thousand CAD | 407.96% |
| 2015 Q4 | 4246.00 CAD | -71.57% |
| 2014 FY | 65.87 Thousand CAD | -32.39% |
| 2014 Q4 | 8717.00 CAD | -44.93% |
| 2014 Q3 | 15.82 Thousand CAD | -46.03% |
| 2014 Q2 | 29.32 Thousand CAD | 1452.51% |
| 2014 Q1 | 1889.00 CAD | -89.97% |
| 2013 FY | 97.43 Thousand CAD | 20.04% |
| 2013 Q4 | 18.83 Thousand CAD | -58.8% |
| 2013 Q3 | 45.7 Thousand CAD | 112.07% |
| 2013 Q2 | 21.55 Thousand CAD | 72.84% |
| 2013 Q1 | 12.46 Thousand CAD | -29.6% |
| 2012 Q4 | 17.71 Thousand CAD | -48.72% |
| 2012 Q2 | 18.3 Thousand CAD | 184.45% |
| 2012 Q1 | 6436.00 CAD | 1936.71% |
| 2012 FY | 81.16 Thousand CAD | -60.92% |
| 2012 Q3 | 34.54 Thousand CAD | 88.69% |
| 2011 Q3 | 45.87 Thousand CAD | -27.48% |
| 2011 FY | 207.71 Thousand CAD | -20.54% |
| 2011 Q4 | 316.00 CAD | -99.31% |
| 2011 Q2 | 63.26 Thousand CAD | 13534.48% |
| 2011 Q1 | 464.00 CAD | -98.77% |
| 2010 Q2 | 50.57 Thousand CAD | 0.89% |
| 2010 Q4 | 37.64 Thousand CAD | -61.78% |
| 2010 Q3 | 98.49 Thousand CAD | 94.76% |
| 2010 Q1 | 50.12 Thousand CAD | -19.42% |
| 2010 FY | 261.41 Thousand CAD | -2.69% |
| 2009 Q1 | 46.02 Thousand CAD | -29.18% |
| 2009 FY | 268.62 Thousand CAD | 480.79% |
| 2009 Q3 | 103.39 Thousand CAD | 90.69% |
| 2009 Q2 | 54.22 Thousand CAD | 17.81% |
| 2009 Q4 | 62.21 Thousand CAD | -39.83% |
| 2008 Q4 | 64.98 Thousand CAD | 124.57% |
| 2008 Q2 | 60.54 Thousand CAD | -15.16% |
| 2008 Q1 | 71.35 Thousand CAD | 14.93% |
| 2008 FY | -70.54 Thousand CAD | -111.46% |
| 2008 Q3 | -264.52 Thousand CAD | -536.94% |
| 2007 Q3 | 450.92 Thousand CAD | 880.22% |
| 2007 Q4 | 62.08 Thousand CAD | -86.23% |
| 2007 Q2 | 46 Thousand CAD | -25.25% |
| 2007 Q1 | 61.54 Thousand CAD | 7.66% |
| 2007 FY | 615.63 Thousand CAD | 159.38% |
| 2006 Q1 | 242.27 Thousand CAD | 314.01% |
| 2006 Q2 | 39 Thousand CAD | -83.9% |
| 2006 FY | 237.35 Thousand CAD | 15.47% |
| 2006 Q4 | 57.16 Thousand CAD | 155.8% |
| 2006 Q3 | -102.44 Thousand CAD | -362.69% |
| 2005 Q4 | 58.52 Thousand CAD | 11.34% |
| 2005 FY | 205.54 Thousand CAD | 2.71% |
| 2005 Q2 | 30.18 Thousand CAD | -38.87% |
| 2005 Q3 | 52.56 Thousand CAD | 74.15% |
| 2005 Q1 | 49.37 Thousand CAD | -32.77% |
| 2004 Q2 | 28.65 Thousand CAD | -34.74% |
| 2004 Q4 | 73.43 Thousand CAD | 3.86% |
| 2004 Q3 | 70.7 Thousand CAD | 146.73% |
| 2004 Q1 | 43.91 Thousand CAD | -22.75% |
| 2004 FY | 200.11 Thousand CAD | -35.15% |
| 2003 FY | 308.59 Thousand CAD | 95.61% |
| 2003 Q4 | 56.84 Thousand CAD | -70.46% |
| 2003 Q2 | 28.82 Thousand CAD | -40.6% |
| 2003 Q3 | 192.46 Thousand CAD | 567.78% |
| 2003 Q1 | 48.51 Thousand CAD | 25.07% |
| 2002 Q2 | 32.12 Thousand CAD | -39.38% |
| 2002 FY | 157.75 Thousand CAD | -18.81% |
| 2002 Q4 | 38.79 Thousand CAD | 17.02% |
| 2002 Q1 | 52.98 Thousand CAD | 34.0% |
| 2002 Q3 | 33.15 Thousand CAD | 3.21% |
| 2001 Q4 | 39.54 Thousand CAD | 4069.98% |
| 2001 FY | 194.3 Thousand CAD | 30.48% |
| 2001 Q3 | -996.00 CAD | -101.19% |
| 2001 Q2 | 83.41 Thousand CAD | -25.45% |
| 2001 Q1 | 111.89 Thousand CAD | 184.12% |
| 2000 Q3 | 42.15 Thousand CAD | 26.96% |
| 2000 Q2 | 33.2 Thousand CAD | -13.1% |
| 2000 Q1 | 38.2 Thousand CAD | 8.08% |
| 2000 FY | 148.91 Thousand CAD | -19.03% |
| 2000 Q4 | 39.38 Thousand CAD | -6.57% |
| 1999 Q1 | 53.63 Thousand CAD | 0.06% |
| 1999 Q2 | 38.63 Thousand CAD | -27.97% |
| 1999 FY | 183.9 Thousand CAD | -20.68% |
| 1999 Q3 | 38.03 Thousand CAD | -1.54% |
| 1999 Q4 | 35.35 Thousand CAD | -7.06% |
| 1998 Q4 | 53.6 Thousand CAD | -25.3% |
| 1998 FY | 231.83 Thousand CAD | -16.85% |
| 1998 Q1 | 62.48 Thousand CAD | 27.08% |
| 1998 Q2 | 48.42 Thousand CAD | -22.5% |
| 1998 Q3 | 71.76 Thousand CAD | 48.18% |
| 1997 Q4 | 49.16 Thousand CAD | -31.72% |
| 1997 Q1 | 110.16 Thousand CAD | 142.79% |
| 1997 Q2 | 51.26 Thousand CAD | -53.46% |
| 1997 FY | 278.81 Thousand CAD | 22.22% |
| 1997 Q3 | 72.01 Thousand CAD | 40.47% |
| 1996 Q4 | 45.37 Thousand CAD | 0.0% |
| 1996 FY | 228.13 Thousand CAD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Absci Corporation | 73.66 Million USD | 64.957% |
| Adaptive Biotechnologies Corporation | 321.75 Million USD | 91.977% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 98.566% |
| Alzamend Neuro, Inc. | 9.93 Million USD | -159.77% |
| Apollomics, Inc. | 54.14 Million USD | 52.318% |
| 180 Life Sciences Corp. | 13.47 Million USD | -91.541% |
| Atossa Therapeutics, Inc. | 31.37 Million USD | 17.726% |
| Bicycle Therapeutics plc | 216.92 Million USD | 88.099% |
| Barinthus Biotherapeutics plc | 84.71 Million USD | 69.528% |
| BioXcel Therapeutics, Inc. | 171.9 Million USD | 84.983% |
| CASI Pharmaceuticals, Inc. | 47 Million USD | 45.081% |
| Chimerix, Inc. | 93.38 Million USD | 72.358% |
| CRISPR Therapeutics AG | 463.49 Million USD | 94.43% |
| Contineum Therapeutics, Inc. Class A Common Stock | 33.72 Million USD | 23.461% |
| EyePoint Pharmaceuticals, Inc. | 116.45 Million USD | 77.832% |
| Fortress Biotech, Inc. | 200.19 Million USD | 87.105% |
| Fortress Biotech, Inc. | 200.19 Million USD | 87.105% |
| Gritstone bio, Inc. | 148.37 Million USD | 82.601% |
| Allakos Inc. | 196.05 Million USD | 86.833% |
| Boundless Bio, Inc. Common Stock | 54.79 Million USD | 52.889% |
| Cara Therapeutics, Inc. | 142.46 Million USD | 81.88% |
| Cytokinetics, Incorporated | 173.61 Million USD | 85.131% |
| enGene Holdings Inc. Common Stock | 25.88 Million USD | 0.27% |
| Innoviva, Inc. | 132.15 Million USD | 80.466% |
| Hoth Therapeutics, Inc. | 7.69 Million USD | -235.598% |
| NLS Pharmaceutics AG | 11.8 Million USD | -118.64% |
| RAPT Therapeutics, Inc. | 127.06 Million USD | 79.683% |
| Salarius Pharmaceuticals, Inc. | 12.89 Thousand USD | -200109.4% |
| Terns Pharmaceuticals, Inc. | 102.55 Million USD | 74.829% |
| Vigil Neuroscience, Inc. | 88.86 Million USD | 70.951% |
| ImmuCell Corporation | 9.61 Million USD | -168.421% |
| IDEAYA Biosciences, Inc. | 157.81 Million USD | 83.642% |
| Incyte Corporation | 1.19 Billion USD | 97.832% |
| Inovio Pharmaceuticals, Inc. | 132.55 Million USD | 80.525% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -283.653% |
| Mustang Bio, Inc. | 48.5 Million USD | 46.774% |
| MiMedx Group, Inc. | 229.72 Million USD | 88.763% |
| MEI Pharma, Inc. | 34.78 Million USD | 25.787% |
| MacroGenics, Inc. | 217.21 Million USD | 88.115% |
| Monopar Therapeutics Inc. | 8.83 Million USD | -192.315% |
| Mereo BioPharma Group plc | 35.84 Million USD | 27.976% |
| Marker Therapeutics, Inc. | 17.89 Million USD | -44.278% |
| Marinus Pharmaceuticals, Inc. | 160.54 Million USD | 83.92% |
| Maravai LifeSciences Holdings, Inc. | 171.85 Million USD | 84.978% |
| Minerva Neurosciences, Inc. | 23.08 Million USD | -11.808% |
| NeuroBo Pharmaceuticals, Inc. | 15.88 Million USD | -62.502% |
| NeuroSense Therapeutics Ltd. | 10.28 Million USD | -150.997% |
| NextCure, Inc. | 67.63 Million USD | 61.833% |
| Orchestra BioMed Holdings, Inc. | 54.08 Million USD | 52.265% |
| Ocuphire Pharma, Inc. | 29.6 Million USD | 12.805% |
| Onconetix, Inc. | 34.9 Million USD | 26.047% |
| Oncternal Therapeutics, Inc. | 12.74 Million USD | -102.534% |
| Opthea Limited | 191.96 Million USD | 86.552% |
| Ovid Therapeutics Inc. | 59.67 Million USD | 56.739% |
| Psyence Biomedical Ltd. | 2.75 Million USD | -838.187% |
| PDS Biotechnology Corporation | 43.04 Million USD | 40.028% |
| Precigen, Inc. | 84.18 Million USD | 69.334% |
| Pieris Pharmaceuticals, Inc. | 72.56 Million USD | 64.425% |
| Prime Medicine, Inc. | 186.63 Million USD | 86.168% |
| PureTech Health plc | 144.59 Million USD | 82.147% |
| Rocket Pharmaceuticals, Inc. | 259.65 Million USD | 90.058% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 99.083% |
| Replimune Group, Inc. | 234.77 Million USD | 89.004% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -198.21% |
| Rigel Pharmaceuticals, Inc. | 130.26 Million USD | 80.182% |
| TransCode Therapeutics, Inc. | 19.41 Million USD | -32.94% |
| Revolution Medicines, Inc. Warrant | 498.76 Million USD | 94.824% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | -6.206% |
| Sesen Bio, Inc. | 78.38 Million USD | 67.065% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | 88.711% |
| Solid Biosciences Inc. | 104.31 Million USD | 75.253% |
| Syndax Pharmaceuticals, Inc. | 229.95 Million USD | 88.774% |
| SciSparc Ltd. | 9.01 Million USD | -186.483% |
| Sutro Biopharma, Inc. | 243 Million USD | 89.377% |
| TG Therapeutics, Inc. | 198.47 Million USD | 86.993% |
| Tonix Pharmaceuticals Holding Corp. | 121.4 Million USD | 78.737% |
| Titan Pharmaceuticals, Inc. | 7.46 Million USD | -245.999% |
| Travere Therapeutics, Inc. | 472 Million USD | 94.531% |
| UroGen Pharma Ltd. | 138.88 Million USD | 81.413% |
| Verrica Pharmaceuticals Inc. | 70.59 Million USD | 63.432% |
| XOMA Corporation | 46.46 Million USD | 44.44% |
| Zentalis Pharmaceuticals, Inc. | 252.55 Million USD | 89.778% |
| AbCellera Biologics Inc. | 275.23 Million USD | 90.621% |
| Longboard Pharmaceuticals, Inc. | 56.75 Million USD | 54.518% |
| Cassava Sciences, Inc. | 105.95 Million USD | 75.636% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -85.591% |
| Precision BioSciences, Inc. | 92.46 Million USD | 72.081% |
| Dyadic International, Inc. | 9.15 Million USD | -182.048% |
| Intensity Therapeutics, Inc. | 8.31 Million USD | -210.314% |
| Eton Pharmaceuticals, Inc. | 22.25 Million USD | -16.007% |
| VYNE Therapeutics Inc. | 29.68 Million USD | 13.028% |
| Tenaya Therapeutics, Inc. | 131.19 Million USD | 80.323% |
| IGM Biosciences, Inc. | 265.59 Million USD | 90.28% |
| X4 Pharmaceuticals, Inc. | 107.52 Million USD | 75.991% |
| Acelyrin, Inc. | 422.06 Million USD | 93.884% |
| Abeona Therapeutics Inc. | 17.93 Million USD | -43.904% |
| Ligand Pharmaceuticals Incorporated | 84.32 Million USD | 69.386% |
| Inhibikase Therapeutics, Inc. | 6.73 Million USD | -283.47% |
| Arcturus Therapeutics Holdings Inc. | 245 Million USD | 89.463% |
| Syros Pharmaceuticals, Inc. | 30.77 Million USD | 16.106% |
| Senti Biosciences, Inc. | 94.7 Million USD | 72.742% |
| Mesoblast Limited | 5.9 Million USD | -337.394% |
| Kymera Therapeutics, Inc. | 244.12 Million USD | 89.425% |
| ChromaDex Corporation | 56.37 Million USD | 54.212% |
| BriaCell Therapeutics Corp. | 33.33 Million USD | 22.547% |
| Akebia Therapeutics, Inc. | 201.11 Million USD | 87.164% |
| Dermata Therapeutics, Inc. | 8.04 Million USD | -221.006% |
| Seer, Inc. | 110.49 Million USD | 76.636% |
| Xeris Biopharma Holdings, Inc. | 168.43 Million USD | 84.674% |
| Novavax, Inc. | 779.12 Million USD | 96.687% |
| Virpax Pharmaceuticals, Inc. | 15.68 Million USD | -64.534% |
| Fate Therapeutics, Inc. | 254.04 Million USD | 89.838% |
| Checkpoint Therapeutics, Inc. | 52.25 Million USD | 50.594% |
| Lyell Immunopharma, Inc. | 247.13 Million USD | 89.554% |
| Celcuity Inc. | 66.23 Million USD | 61.022% |
| ContextLogic Inc. | 387 Million USD | 93.329% |
| Phathom Pharmaceuticals, Inc. | 167.82 Million USD | 84.618% |
| HOOKIPA Pharma Inc. | 32.74 Million USD | 21.166% |
| Jazz Pharmaceuticals plc | 3.25 Billion USD | 99.207% |
| Amarin Corporation plc | 272.35 Million USD | 90.522% |
| AnaptysBio, Inc. | 181.56 Million USD | 85.782% |
| Aptevo Therapeutics Inc. | 28.87 Million USD | 10.607% |
| Aptorum Group Limited | 10.56 Thousand USD | -244221.408% |
| Cartesian Therapeutics, Inc. | 110.86 Million USD | 76.715% |
| Arrowhead Pharmaceuticals, Inc. | 445.73 Million USD | 94.208% |
| Ardelyx, Inc. | 169.93 Million USD | 84.809% |
| Celularity Inc. | 215.05 Million USD | 87.996% |
| Omeros Corporation | 94.75 Million USD | 72.755% |
| Humacyte, Inc. | 23.49 Million USD | -9.865% |
| Immunocore Holdings plc | 308.04 Million USD | 91.62% |
| IO Biotech, Inc. | 91.44 Million USD | 71.769% |
| GT Biopharma, Inc. | 13.57 Million USD | -90.152% |
| Cabaletta Bio, Inc. | 74.66 Million USD | 65.423% |
| Summit Therapeutics Inc. | 87.68 Million USD | 70.56% |
| Alaunos Therapeutics, Inc. | 29.46 Million USD | 12.399% |
| Pulmatrix, Inc. | 22.03 Million USD | -17.139% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | 95.32% |
| Evogene Ltd. | 27.79 Million USD | 7.107% |
| CorMedix Inc. | 48.95 Million USD | 47.271% |
| BioLineRx Ltd. | 50.8 Million USD | 49.185% |
| VistaGen Therapeutics, Inc. | 34.08 Million USD | 24.263% |
| Sagimet Biosciences Inc. | 32.74 Million USD | 21.151% |
| PTC Therapeutics, Inc. | 1.31 Billion USD | 98.032% |
| scPharmaceuticals Inc. | 65.17 Million USD | 60.393% |
| Fulcrum Therapeutics, Inc. | 113.46 Million USD | 77.249% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | 92.997% |
| NLS Pharmaceutics AG | 11.8 Million USD | -118.64% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | -6.206% |
| Akero Therapeutics, Inc. | 172.87 Million USD | 85.067% |
| Eliem Therapeutics, Inc. | 37.4 Million USD | 30.991% |
| Lisata Therapeutics, Inc. | 25.7 Million USD | -0.416% |
| Stoke Therapeutics, Inc. | 123.55 Million USD | 79.106% |
| Reneo Pharmaceuticals, Inc. | 83.05 Million USD | 68.917% |
| Outlook Therapeutics, Inc. | 53.12 Million USD | 51.408% |
| ProMIS Neurosciences, Inc. | 8.45 Million USD | -205.404% |
| Daré Bioscience, Inc. | 33.6 Million USD | 23.191% |
| bluebird bio, Inc. | 240.23 Million USD | 89.254% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 98.522% |
| DBV Technologies S.A. | 92.16 Million USD | 71.989% |
| Avidity Biosciences, Inc. | 245.15 Million USD | 89.47% |
| Galecto, Inc. | 35.62 Million USD | 27.541% |
| Sensei Biotherapeutics, Inc. | 37.06 Million USD | 30.35% |
| Spruce Biosciences, Inc. | 62.08 Million USD | 58.418% |
| Inhibrx Biosciences, Inc. | 219.83 Million USD | 88.257% |
| GlycoMimetics, Inc. | 39.28 Million USD | 34.288% |
| Arcutis Biotherapeutics, Inc. | 295.72 Million USD | 91.27% |
| ADMA Biologics, Inc. | 66.58 Million USD | 61.231% |
| Clene Inc. | 41.07 Million USD | 37.148% |
| Recursion Pharmaceuticals, Inc. | 352.04 Million USD | 92.667% |
| Aptose Biosciences Inc. | 52.35 Million USD | 50.693% |
| ZyVersa Therapeutics, Inc. | 14.41 Million USD | -79.142% |
| Soligenix, Inc. | 7.79 Million USD | -231.163% |
| Century Therapeutics, Inc. | 56.07 Million USD | 53.96% |
| Kura Oncology, Inc. | 165.8 Million USD | 84.43% |
| Surrozen, Inc. | 18.55 Million USD | -39.164% |
| TScan Therapeutics, Inc. | 114.5 Million USD | 77.456% |
| Ocean Biomedical, Inc. | 2.48 Million USD | -940.24% |
| CytomX Therapeutics, Inc. | 107.69 Million USD | 76.03% |
| Autolus Therapeutics plc | 196.72 Million USD | 86.878% |
| Mineralys Therapeutics, Inc. | 84.65 Million USD | 69.506% |
| Eterna Therapeutics Inc. | 19.38 Million USD | -33.184% |
| Caribou Biosciences, Inc. | 150.53 Million USD | 82.851% |
| GRI Bio, Inc. | 11.33 Million USD | -127.846% |
| Xenetic Biosciences, Inc. | 7.05 Million USD | -265.874% |
| Janux Therapeutics, Inc. | 81.06 Million USD | 68.154% |
| INmune Bio, Inc. | 29.89 Million USD | 13.651% |
| Heron Therapeutics, Inc. | 172.55 Million USD | 85.039% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | 35.966% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -61.552% |
| Tenax Therapeutics, Inc. | 8.23 Million USD | -213.519% |
| Jaguar Health, Inc. | 42.01 Million USD | 38.558% |
| Entero Therapeutics, Inc. | 15.74 Million USD | -63.993% |
| Milestone Pharmaceuticals Inc. | 62.09 Million USD | 58.429% |
| Clearside Biomedical, Inc. | 32.71 Million USD | 21.091% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | 90.636% |
| Coherus BioSciences, Inc. | 301.45 Million USD | 91.436% |
| Verastem, Inc. | 92.08 Million USD | 71.966% |
| Pliant Therapeutics, Inc. | 185.72 Million USD | 86.1% |
| Histogen Inc. | 14.27 Million USD | -80.879% |
| Aprea Therapeutics, Inc. | 16.04 Million USD | -60.86% |
| ACADIA Pharmaceuticals Inc. | 754.08 Million USD | 96.577% |
| Surrozen, Inc. | 18.55 Million USD | -39.164% |
| Organovo Holdings, Inc. | 14.91 Million USD | -73.081% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -407.147% |
| Cadrenal Therapeutics, Inc. Common Stock | 7.63 Million USD | -238.209% |
| Centessa Pharmaceuticals plc | 178.13 Million USD | 85.508% |
| Hepion Pharmaceuticals, Inc. | 48.44 Million USD | 46.716% |
| BioRestorative Therapies, Inc. | 15.36 Million USD | -67.995% |
| Kronos Bio, Inc. | 128.11 Million USD | 79.851% |
| Turnstone Biologics Corp. | 78.33 Million USD | 67.047% |
| Synaptogenix, Inc. | 8.31 Million USD | -210.506% |
| Tiziana Life Sciences Ltd | 14.58 Million USD | -76.985% |
| Entrada Therapeutics, Inc. | 132.17 Million USD | 80.469% |
| Aurinia Pharmaceuticals Inc. | 253.05 Million USD | 89.799% |
| Exelixis, Inc. | 1.58 Billion USD | 98.373% |
| Nurix Therapeutics, Inc. | 232.05 Million USD | 88.875% |
| Apellis Pharmaceuticals, Inc. | 855.2 Million USD | 96.981% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | 62.511% |
| ESSA Pharma Inc. | 32.13 Million USD | 19.665% |
| TNF Pharmaceuticals, Inc. | 16.36 Million USD | -57.791% |
| Avid Bioservices, Inc. | 25.99 Million USD | 0.696% |
| Insmed Incorporated | 949.26 Million USD | 97.281% |
| MediWound Ltd. | 18.86 Million USD | -36.819% |
| OmniAb, Inc. | 83.89 Million USD | 69.229% |
| Alector, Inc. | 248.8 Million USD | 89.624% |
| Seres Therapeutics, Inc. | 234.3 Million USD | 88.982% |
| Zai Lab Limited | 547.47 Million USD | 95.285% |
| AlloVir, Inc. | 180.93 Million USD | 85.732% |
| Revance Therapeutics, Inc. | 398.65 Million USD | 93.524% |
| ORIC Pharmaceuticals, Inc. | 110.78 Million USD | 76.697% |
| Aura Biosciences, Inc. | 84.99 Million USD | 69.626% |
| Immunic, Inc. | 99.22 Million USD | 73.983% |
| Tarsus Pharmaceuticals, Inc. | 159.01 Million USD | 83.765% |
| Veracyte, Inc. | 357.93 Million USD | 92.788% |
| InMed Pharmaceuticals Inc. | 9.01 Billion USD | 99.714% |
| FibroGen, Inc. | 398.11 Million USD | 93.516% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -81.668% |
| Catalyst Pharmaceuticals, Inc. | 259.42 Million USD | 90.049% |
| Adial Pharmaceuticals, Inc. | 6.88 Million USD | -274.785% |
| Sonnet BioTherapeutics Holdings, Inc. | 7.12 Million USD | -262.279% |
| Cyclacel Pharmaceuticals, Inc. | 25.87 Million USD | 0.224% |
| Amylyx Pharmaceuticals, Inc. | 316.54 Million USD | 91.845% |
| Fortrea Holdings Inc. | 457.3 Million USD | 94.355% |
| KalVista Pharmaceuticals, Inc. | 54.27 Million USD | 52.439% |
| XBiotech Inc. | 37.51 Million USD | 31.178% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | 62.511% |
| Keros Therapeutics, Inc. | 169.27 Million USD | 84.75% |
| SELLAS Life Sciences Group, Inc. | 37.86 Million USD | 31.831% |
| Lyra Therapeutics, Inc. | 20.64 Million USD | -25.018% |
| Foghorn Therapeutics Inc. | 142.06 Million USD | 81.828% |
| Agenus Inc. | 78.18 Million USD | 66.981% |
| Y-mAbs Therapeutics, Inc. | 99.07 Million USD | 73.944% |
| Theravance Biopharma, Inc. | 110.71 Million USD | 76.684% |
| Ultragenyx Pharmaceutical Inc. | 958.24 Million USD | 97.306% |
| Metagenomi, Inc. Common Stock | 28.84 Million USD | 10.504% |
| BioCryst Pharmaceuticals, Inc. | 430.64 Million USD | 94.005% |
| Gain Therapeutics, Inc. | 22.3 Million USD | -15.719% |
| C4 Therapeutics, Inc. | 159.78 Million USD | 83.844% |
| Creative Medical Technology Holdings, Inc. | 5.53 Million USD | -366.737% |
| Chemomab Therapeutics Ltd. | 25.45 Million USD | -1.398% |
| Lantern Pharma Inc. | 17.87 Million USD | -44.399% |
| Eledon Pharmaceuticals, Inc. | 43 Million USD | 39.965% |
| Ainos, Inc. | 12.95 Million USD | -99.303% |
| Pluri Inc. | 22.48 Million USD | -14.835% |
| Prothena Corporation plc | 282.4 Million USD | 90.859% |
| Adaptimmune Therapeutics plc | 200.02 Million USD | 87.094% |
| Rallybio Corporation | 78.93 Million USD | 67.295% |
| Kodiak Sciences Inc. | 277.32 Million USD | 90.691% |
| Cue Biopharma, Inc. | 19.54 Million USD | -32.1% |
| MeiraGTx Holdings plc | 151.07 Million USD | 82.913% |
| Annexon, Inc. | 143.72 Million USD | 82.038% |
| Assembly Biosciences, Inc. | 22.9 Million USD | -12.685% |
| Moderna, Inc. | 6.39 Billion USD | 99.596% |
| Cocrystal Pharma, Inc. | 3.39 Million USD | -661.504% |
| Cidara Therapeutics, Inc. | 86.86 Million USD | 70.281% |
| Blueprint Medicines Corporation | 722.86 Million USD | 96.429% |
| Immix Biopharma, Inc. | 16.14 Million USD | -59.933% |
| CalciMedica, Inc. | 21.81 Million USD | -18.325% |
| Monte Rosa Therapeutics, Inc. | 143.31 Million USD | 81.987% |
| Scholar Rock Holding Corporation | 171.29 Million USD | 84.93% |
| Wave Life Sciences Ltd. | 181.3 Million USD | 85.761% |
| Sana Biotechnology, Inc. | 294.94 Million USD | 91.247% |
| Elicio Therapeutics, Inc. | 34.57 Million USD | 25.336% |
| Adlai Nortye Ltd. American Depositary Shares | 72.55 Million USD | 64.418% |
| Nutriband Inc. | 5.73 Million USD | -350.207% |
| Protara Therapeutics, Inc. | 43.61 Million USD | 40.809% |
| Vor Biopharma Inc. | 126.03 Million USD | 79.518% |
| Roivant Sciences Ltd. | 1.18 Billion USD | 97.829% |
| Alkermes plc | 996.24 Million USD | 97.409% |
| ProKidney Corp. | 151.52 Million USD | 82.963% |
| Applied Therapeutics, Inc. | 74.17 Million USD | 65.197% |
| Arcellx, Inc. | 200.19 Million USD | 87.105% |
| BridgeBio Pharma, Inc. | 614.22 Million USD | 95.797% |
| Tango Therapeutics, Inc. | 150.7 Million USD | 82.87% |
| Galectin Therapeutics Inc. | 38.07 Million USD | 32.194% |
| Atai Life Sciences N.V. | 125.78 Million USD | 79.477% |
| Renovaro Biosciences Inc. | 81.63 Million USD | 68.379% |
| Aerovate Therapeutics, Inc. | 81.4 Million USD | 68.29% |
| MediciNova, Inc. | 10.9 Million USD | -136.829% |
| Praxis Precision Medicines, Inc. | 128.82 Million USD | 79.96% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -255.602% |
| GeoVax Labs, Inc. | 6.02 Million USD | -328.666% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | 94.581% |
| Biomea Fusion, Inc. | 126.13 Million USD | 79.534% |
| RenovoRx, Inc. | 11.39 Million USD | -126.527% |
| Cullinan Oncology, Inc. | 191.08 Million USD | 86.491% |
| Geron Corporation | 70.44 Million USD | 63.352% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | 6.406% |
| 4D Molecular Therapeutics, Inc. | 133.59 Million USD | 80.676% |
| Dyne Therapeutics, Inc. | 242.16 Million USD | 89.34% |
| Kiniksa Pharmaceuticals, Ltd. | 262.04 Million USD | 90.149% |
| Royalty Pharma plc | 862.4 Million USD | 97.007% |
| Ventyx Biosciences, Inc. | 207.99 Million USD | 87.589% |
| Imunon, Inc. | 20.31 Million USD | -27.102% |
| BioAtla, Inc. | 129.68 Million USD | 80.094% |
| Allogene Therapeutics, Inc. | 84.91 Million USD | 69.6% |
| Larimar Therapeutics, Inc. | 41.75 Million USD | 38.18% |
| Mersana Therapeutics, Inc. | 207.81 Million USD | 87.578% |
| Structure Therapeutics Inc. | 102.77 Million USD | 74.882% |
| 89bio, Inc. | 151.2 Million USD | 82.927% |
| Kezar Life Sciences, Inc. | 111.17 Million USD | 76.779% |
| aTyr Pharma, Inc. | 12.97 Million USD | -98.898% |
| Aligos Therapeutics, Inc. | 103.65 Million USD | 75.096% |
| Viridian Therapeutics, Inc. | 254.76 Million USD | 89.867% |
| EyeGate Pharmaceuticals, Inc. | 8.22 Million USD | -213.867% |
| Akari Therapeutics, Plc | 16.8 Million USD | -53.606% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -1035.239% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | 91.375% |
| Lexicon Pharmaceuticals, Inc. | 172.86 Million USD | 85.067% |
| Liquidia Corporation | 87.98 Million USD | 70.659% |
| Entera Bio Ltd. | 8.86 Million USD | -191.366% |
| GH Research PLC | 41.22 Million USD | 37.376% |
| Vericel Corporation | 142.04 Million USD | 81.826% |
| Arbutus Biopharma Corporation | 22.54 Million USD | -14.509% |
| Xencor, Inc. | 306.97 Million USD | 91.591% |
| 60 Degrees Pharmaceuticals, Inc. | 4.93 Million USD | -423.248% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -61.552% |
| Coeptis Therapeutics Holdings, Inc. | 20.48 Million USD | -25.989% |
| Vaxcyte, Inc. | 468.04 Million USD | 94.484% |
| Xenon Pharmaceuticals Inc. | 46.54 Million USD | 44.534% |
| Vanda Pharmaceuticals Inc. | 191.79 Million USD | 86.54% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -283.653% |
| Portage Biotech Inc. | 18.19 Million USD | -41.848% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -255.602% |
| Olema Pharmaceuticals, Inc. | 104.96 Million USD | 75.405% |
| OncoCyte Corporation | 25.63 Million USD | -0.694% |
| Qualigen Therapeutics, Inc. | 6.09 Million USD | -323.502% |
| Processa Pharmaceuticals, Inc. | 11.45 Million USD | -125.32% |
| Purple Biotech Ltd. | -22.46 Million USD | 214.902% |
| Tempest Therapeutics, Inc. | 29.15 Million USD | 11.462% |
| Sol-Gel Technologies Ltd. | 30.85 Million USD | 16.345% |
| Rhythm Pharmaceuticals, Inc. | 252.48 Million USD | 89.776% |
| CollPlant Biotechnologies Ltd. | 16.48 Million USD | -56.644% |
| Moleculin Biotech, Inc. | 29.63 Million USD | 12.878% |
| United Therapeutics Corporation | 885.1 Million USD | 97.083% |
| HilleVax, Inc. | 133.34 Million USD | 80.64% |
| Silo Pharma, Inc. | 3.92 Million USD | -558.234% |
| Telomir Pharmaceuticals, Inc. Common Stock | 3.94 Million USD | -554.863% |
| Pharming Group N.V. | 225.49 Million USD | 88.552% |
| Tharimmune, Inc. | 9.45 Million USD | -173.024% |
| Genprex, Inc. | 31.06 Million USD | 16.888% |
| Apogee Therapeutics, Inc. | 93 Million USD | 72.243% |
| Neumora Therapeutics, Inc. Common Stock | 187.52 Million USD | 86.234% |
| Pyxis Oncology, Inc. | 82.19 Million USD | 68.593% |
| XTL Biopharmaceuticals Ltd. | 765 Thousand USD | -3274.51% |
| Virios Therapeutics, Inc. | 5.44 Million USD | -373.938% |
| OKYO Pharma Limited | 8243.57 USD | -313053.161% |
| Savara Inc. | 15.74 Million USD | -63.957% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -47.878% |
| Curis, Inc. | 58.35 Million USD | 55.762% |
| Carmell Therapeutics Corporation | 5.09 Million USD | -406.923% |
| Achieve Life Sciences, Inc. | 27.02 Million USD | 4.467% |
| BeiGene, Ltd. | 3.28 Billion USD | 99.215% |
| Protagonist Therapeutics, Inc. | 153.65 Million USD | 83.199% |
| Erasca, Inc. | 141.52 Million USD | 81.759% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -470.248% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -470.248% |
| Vincerx Pharma, Inc. | 42.6 Million USD | 39.414% |
| Fresh Tracks Therapeutics, Inc. | 14.36 Million USD | -79.695% |
| Acrivon Therapeutics, Inc. Common Stock | 66.7 Million USD | 61.297% |
| Celldex Therapeutics, Inc. | 43.41 Million USD | 40.538% |
| Cogent Biosciences, Inc. | 208.13 Million USD | 87.597% |
| Adicet Bio, Inc. | 152.03 Million USD | 83.021% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | 93.964% |
| Aditxt, Inc. | 25.95 Million USD | 0.523% |
| Adagene Inc. | 41.83 Million USD | 38.288% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -253.142% |
| Quantum-Si incorporated | 111.65 Million USD | 76.881% |
| Acurx Pharmaceuticals, Inc. | 14.57 Million USD | -77.085% |
| Voyager Therapeutics, Inc. | 35.82 Million USD | 27.935% |
| Compugen Ltd. | 43.97 Million USD | 41.291% |
| Generation Bio Co. | 144.46 Million USD | 82.131% |
| Astria Therapeutics, Inc. | 83.03 Million USD | 68.909% |
| Black Diamond Therapeutics, Inc. | 86.46 Million USD | 70.142% |
| Invivyd, Inc. | 205.75 Million USD | 87.454% |
| Relay Therapeutics, Inc. | 72.15 Million USD | 64.225% |
| Quoin Pharmaceuticals, Ltd. | 9.37 Million USD | -175.257% |
| Spero Therapeutics, Inc. | 75.25 Million USD | 65.696% |
| Artelo Biosciences, Inc. | 10.28 Million USD | -150.948% |
| 2seventy bio, Inc. | 289.88 Million USD | 91.095% |
| Instil Bio, Inc. | 85.78 Million USD | 69.907% |
| Capricor Therapeutics, Inc. | 12.8 Million USD | -101.556% |
| Elevai Labs, Inc. Common Stock | 1.13 Million USD | -2175.291% |
| GeoVax Labs, Inc. | 6.02 Million USD | -328.666% |
| Citius Pharmaceuticals, Inc. | 36.73 Million USD | 29.721% |
| Relmada Therapeutics, Inc. | 103.7 Million USD | 75.107% |
| ALX Oncology Holdings Inc. | 170.27 Million USD | 84.839% |
| Vir Biotechnology, Inc. | 767.72 Million USD | 96.637% |
| Evaxion Biotech A/S | 22.27 Million USD | -15.918% |
| Ocular Therapeutix, Inc. | 135.54 Million USD | 80.955% |
| Verve Therapeutics, Inc. | 234.88 Million USD | 89.009% |
| Tyra Biosciences, Inc. | 79.94 Million USD | 67.709% |
| Cingulate Inc. | 22.75 Million USD | -13.427% |
| Galmed Pharmaceuticals Ltd. | -7.49 Million USD | 444.568% |
| Unity Biotechnology, Inc. | 44.66 Million USD | 42.206% |
| Connect Biopharma Holdings Limited | 62.07 Million USD | 58.413% |
| Clearmind Medicine Inc. | 8.74 Million USD | -195.321% |
| Bolt Biotherapeutics, Inc. | 84.07 Million USD | 69.294% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -780.161% |
| Viking Therapeutics, Inc. | 100.82 Million USD | 74.397% |
| Madrigal Pharmaceuticals, Inc. | 380.49 Million USD | 93.215% |
| ImmunityBio, Inc. | 362.87 Million USD | 92.886% |
| Korro Bio, Inc. | 84.53 Million USD | 69.462% |
| Kineta, Inc. | 21.15 Million USD | -22.022% |
| BioVie Inc. | 31.95 Million USD | 19.202% |
| Codexis, Inc. | 66.51 Million USD | 61.191% |
| Celularity Inc. | 215.05 Million USD | 87.996% |
| Aileron Therapeutics, Inc. | 16.27 Million USD | -58.608% |
| Crinetics Pharmaceuticals, Inc. | 226.62 Million USD | 88.609% |
| Virax Biolabs Group Limited | 6.54 Million USD | -294.299% |
| Cibus, Inc. | 320.3 Million USD | 91.94% |
| IN8bio, Inc. | 30.33 Million USD | 14.906% |
| Adverum Biotechnologies, Inc. | 127.59 Million USD | 79.767% |
| Avalo Therapeutics, Inc. | 640 Thousand USD | -3933.594% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | 96.689% |
| Eyenovia, Inc. | 25.4 Million USD | -1.608% |
| Puma Biotechnology, Inc. | 140.31 Million USD | 81.602% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -364.132% |
| Elevation Oncology, Inc. | 45.44 Million USD | 43.195% |
| Xilio Therapeutics, Inc. | 79.13 Million USD | 67.378% |
| Cardiff Oncology, Inc. | 45.9 Million USD | 43.758% |
| Enanta Pharmaceuticals, Inc. | 216.41 Million USD | 88.071% |
| Regulus Therapeutics Inc. | 9.95 Million USD | -159.265% |
| Moolec Science SA | 52.75 Million USD | 51.062% |
| Acumen Pharmaceuticals, Inc. | 61.13 Million USD | 57.776% |
| LAVA Therapeutics N.V. | 46.54 Million USD | 44.532% |
| Atea Pharmaceuticals, Inc. | 94.07 Million USD | 72.558% |
| Compass Therapeutics, Inc. | 48.47 Million USD | 46.744% |
| Greenwich LifeSciences, Inc. | 9.32 Million USD | -176.751% |
| TFF Pharmaceuticals, Inc. | 22.62 Million USD | -14.082% |
| Humacyte, Inc. | 23.49 Million USD | -9.865% |
| PMV Pharmaceuticals, Inc. | 80.13 Million USD | 67.784% |
| Avenue Therapeutics, Inc. | 14.54 Million USD | -77.545% |
| Genelux Corporation | 24.33 Million USD | -6.082% |
| Trevi Therapeutics, Inc. | 33.92 Million USD | 23.901% |
| Notable Labs, Ltd. | 14.77 Million USD | -74.78% |
| Immunovant, Inc. | 282.7 Million USD | 90.869% |
| Quantum-Si incorporated | 111.65 Million USD | 76.881% |
| DiaMedica Therapeutics Inc. | 21.26 Million USD | -21.385% |
| Vera Therapeutics, Inc. | 102.01 Million USD | 74.694% |
| Acasti Pharma Inc. | 11.3 Million USD | -128.431% |
| MiNK Therapeutics, Inc. | 22.92 Million USD | -12.625% |
| Soleno Therapeutics, Inc. | 41.38 Million USD | 37.621% |
| PepGen Inc. | 84.76 Million USD | 69.546% |
| Nuvectis Pharma, Inc. | 22.89 Million USD | -12.744% |
| BriaCell Therapeutics Corp. | 32.72 Million USD | 21.117% |
| Immuneering Corporation | 58.41 Million USD | 55.806% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -407.147% |
| Belite Bio, Inc | 31.66 Million USD | 18.482% |
| XOMA Corporation | 46.46 Million USD | 44.44% |
| ARS Pharmaceuticals, Inc. | 67.55 Million USD | 61.784% |
| Bionomics Limited | 17.89 Billion USD | 99.856% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 172.351% |
| uniQure N.V. | 285.08 Million USD | 90.945% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -253.142% |
| Poseida Therapeutics, Inc. | 194.2 Million USD | 86.707% |
| Forte Biosciences, Inc. | 32.47 Million USD | 20.513% |
| Anebulo Pharmaceuticals, Inc. | 8.3 Million USD | -210.696% |
| Enlivex Therapeutics Ltd. | 29.39 Million USD | 12.179% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -364.132% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -81.668% |
| FibroBiologics, Inc. Common Stock | 8.88 Million USD | -190.415% |
| Altimmune, Inc. | 30.55 Million USD | 15.516% |
| LENZ Therapeutics, Inc. | 70.7 Million USD | 63.488% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 172.351% |
| Peak Bio, Inc. | 1249.13 USD | -2066538.38% |
| Zevra Therapeutics, Inc. | 74.12 Million USD | 65.171% |
| Benitec Biopharma Inc. | 22.38 Million USD | -15.338% |
| Spyre Therapeutics, Inc. | 243.18 Million USD | 89.385% |
| NKGen Biotech, Inc. Common Stock | 28.54 Million USD | 9.558% |
| Zura Bio Limited | 62.63 Million USD | 58.787% |
| PolyPid Ltd. | 21.04 Million USD | -22.666% |
| NKGen Biotech, Inc. Warrants | 28.54 Million USD | 9.558% |
| argenx SE | 1.53 Billion USD | 98.317% |
| Immunome, Inc. | 122.82 Million USD | 78.981% |
| Verona Pharma plc | 67.15 Million USD | 61.557% |
| enGene Holdings Inc. Warrants | 25.88 Million USD | 0.27% |
| Shattuck Labs, Inc. | 93.61 Million USD | 72.424% |
| CervoMed Inc. | 14.95 Million USD | -72.586% |
| Plus Therapeutics, Inc. | 8.54 Million USD | -202.142% |
| Dianthus Therapeutics, Inc. | 51 Million USD | 49.382% |
| Moolec Science SA | 52.75 Million USD | 51.062% |
| Enveric Biosciences, Inc. | 16.44 Million USD | -56.945% |
| Design Therapeutics, Inc. | 78.19 Million USD | 66.984% |
| Leap Therapeutics, Inc. | 87.04 Million USD | 70.342% |
| Seelos Therapeutics, Inc. | 12.58 Million USD | -105.125% |
| Achilles Therapeutics plc | 75.25 Million USD | 65.697% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -780.161% |
| CG Oncology, Inc. Common stock | 55.65 Million USD | 53.614% |
| Fractyl Health, Inc. Common Stock | 50.87 Million USD | 49.262% |
| Rani Therapeutics Holdings, Inc. | 66.09 Million USD | 60.945% |
| MoonLake Immunotherapeutics | 54.12 Million USD | 52.303% |
| Tourmaline Bio, Inc. | 45.4 Million USD | 43.15% |
| Beam Therapeutics Inc. | 554.19 Million USD | 95.342% |
| Mirum Pharmaceuticals, Inc. | 248.48 Million USD | 89.611% |
| AEON Biopharma, Inc. | 48.42 Million USD | 46.695% |
| Aadi Bioscience, Inc. | 93.47 Million USD | 72.384% |
| Enliven Therapeutics, Inc. | 83.52 Million USD | 69.095% |
| Kiora Pharmaceuticals, Inc. | 12.58 Million USD | -105.094% |
| NeurAxis, Inc. | 8.82 Million USD | -192.647% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | 94.276% |
| Lumos Pharma, Inc. | 38.66 Million USD | 33.234% |
| Opiant Pharmaceuticals, Inc. | 26.5 Million USD | 2.594% |
| Palisade Bio, Inc. | 13.32 Million USD | -93.806% |
| Nutriband Inc. | 5.73 Million USD | -350.207% |
| Taysha Gene Therapies, Inc. | 87.89 Million USD | 70.628% |
| Neurogene Inc. | 55.58 Million USD | 53.556% |
| Kintara Therapeutics, Inc. | 8.45 Million USD | -205.467% |
| CARGO Therapeutics, Inc. Common Stock | 96.71 Million USD | 73.307% |
| Athira Pharma, Inc. | 125.46 Million USD | 79.425% |
| HCW Biologics Inc. | 21.02 Million USD | -22.768% |
| XOMA Corporation | 46.46 Million USD | 44.44% |
| Nektar Therapeutics | 190.9 Million USD | 86.477% |
| Arvinas, Inc. | 480 Million USD | 94.622% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -1035.239% |
| Merus N.V. | 200.49 Million USD | 87.124% |
| Omega Therapeutics, Inc. | 103.35 Million USD | 75.023% |
| Quince Therapeutics, Inc. | 34.62 Million USD | 25.433% |
| Rezolute, Inc. | 70.38 Million USD | 63.324% |
| Clene Inc. | 41.07 Million USD | 37.148% |
| Indaptus Therapeutics, Inc. | 16.37 Million USD | -57.615% |
| BeyondSpring Inc. | 24.86 Million USD | -3.821% |
| Synlogic, Inc. | 58.53 Million USD | 55.896% |
| Allarity Therapeutics, Inc. | 17.89 Million USD | -44.282% |
| Phio Pharmaceuticals Corp. | 4.49 Million USD | -474.688% |
| Peak Bio, Inc. | 1249.13 USD | -2066538.38% |
| Werewolf Therapeutics, Inc. | 60.44 Million USD | 57.292% |
| Krystal Biotech, Inc. | 160.42 Million USD | 83.908% |
| Karyopharm Therapeutics Inc. | 270.63 Million USD | 90.461% |
| SpringWorks Therapeutics, Inc. | 348.03 Million USD | 92.583% |
| Lipella Pharmaceuticals Inc. | 2.15 Million USD | -1096.949% |
| MannKind Corporation | 125.59 Million USD | 79.446% |
| Ikena Oncology, Inc. | 84.57 Million USD | 69.478% |
| Cyclerion Therapeutics, Inc. | 9.64 Million USD | -167.596% |
| Gyre Therapeutics, Inc. | 89.6 Million USD | 71.189% |
| Gossamer Bio, Inc. | 183.75 Million USD | 85.952% |
| CohBar, Inc. | 12.38 Million USD | -108.382% |
| Cognition Therapeutics, Inc. | 50.72 Million USD | 49.107% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | 6.406% |
| Legend Biotech Corporation | 583.14 Million USD | 95.573% |
| Mural Oncology plc | 192.07 Million USD | 86.56% |
| Disc Medicine, Inc. | 91.12 Million USD | 71.671% |
| Champions Oncology, Inc. | 28.11 Million USD | 8.164% |
| REGENXBIO Inc. | 321.15 Million USD | 91.962% |
| Ensysce Biosciences, Inc. | 5.36 Million USD | -381.512% |
| Anavex Life Sciences Corp. | 55.75 Million USD | 53.7% |
| Cellectar Biosciences, Inc. | 38.96 Million USD | 33.741% |
| Edgewise Therapeutics, Inc. | 114.35 Million USD | 77.426% |
| Vaxart, Inc. | 90.72 Million USD | 71.546% |
| PharmaCyte Biotech, Inc. | 8.52 Million USD | -202.993% |
| Aldeyra Therapeutics, Inc. | 42.79 Million USD | 39.676% |
| Cellectis S.A. | 97.32 Million USD | 73.474% |
| Longeveron Inc. | 21.25 Million USD | -21.482% |
| Repare Therapeutics Inc. | 167.35 Million USD | 84.575% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | 98.103% |
| Inozyme Pharma, Inc. | 75.64 Million USD | 65.873% |
| Revolution Medicines, Inc. | 498.76 Million USD | 94.824% |
| Nymox Pharmaceutical Corporation | 6.65 Million USD | -288.079% |
| Third Harmonic Bio, Inc. | 43.95 Million USD | 41.268% |
| ArriVent BioPharma, Inc. Common Stock | 74.59 Million USD | 65.391% |
| AN2 Therapeutics, Inc. | 69.63 Million USD | 62.928% |
| Anixa Biosciences, Inc. | 11.06 Million USD | -133.409% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 99.459% |
| Denali Therapeutics Inc. | 527.23 Million USD | 95.104% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -198.21% |
| Veru Inc. | 101.34 Million USD | 74.528% |
| Corvus Pharmaceuticals, Inc. | 23.4 Million USD | -10.288% |
| Cingulate Inc. | 22.75 Million USD | -13.427% |
| Passage Bio, Inc. | 108.38 Million USD | 76.183% |
| Context Therapeutics Inc. | 25.07 Million USD | -2.961% |
| Exicure, Inc. | 14.07 Million USD | -83.397% |
| Day One Biopharmaceuticals, Inc. | 206.06 Million USD | 87.472% |
| Oramed Pharmaceuticals Inc. | 43.3 Million USD | 40.382% |
| Scinai Immunotherapeutics Ltd. | 9.17 Million USD | -181.292% |
| Nuvalent, Inc. | 149.49 Million USD | 82.732% |
| ABVC BioPharma, Inc. | 8.06 Million USD | -220.011% |
| Carisma Therapeutics, Inc. | 103.65 Million USD | 75.094% |
| Unicycive Therapeutics, Inc. | 21.44 Million USD | -20.355% |
| OmniAb, Inc. | 83.89 Million USD | 69.229% |
| Anew Medical, Inc. | 1.3 Million USD | -1884.485% |
| Fennec Pharmaceuticals Inc. | 32.76 Million USD | 21.209% |
| Lipocine Inc. | 15.08 Million USD | -71.185% |
| Lexeo Therapeutics, Inc. Common Stock | 68.51 Million USD | 62.321% |
| Nautilus Biotechnology, Inc. | 76.15 Million USD | 66.101% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | 35.966% |
| G1 Therapeutics, Inc. | 114.84 Million USD | 77.521% |
| Bellerophon Therapeutics, Inc. | 22.38 Million USD | -15.328% |
| Sage Therapeutics, Inc. | 664.14 Million USD | 96.113% |
| Ocugen, Inc. | 71.56 Million USD | 63.929% |
| Mind Medicine (MindMed) Inc. | 93.86 Million USD | 72.498% |
| Q32 Bio Inc. | 92.68 Million USD | 72.146% |
| Brainstorm Cell Therapeutics Inc. | 21.17 Million USD | -21.918% |
| Alumis Inc. Common Stock | 158.17 Million USD | 83.679% |
| Equillium, Inc. | 50.6 Million USD | 48.988% |
| Kyverna Therapeutics, Inc. | 62.4 Million USD | 58.634% |
| Coya Therapeutics, Inc. | 13.9 Million USD | -85.645% |
| CNS Pharmaceuticals, Inc. | 18.86 Million USD | -36.84% |
| Dominari Holdings Inc. | 23.83 Million USD | -8.307% |
| Edesa Biotech, Inc. | 9.22 Million USD | -179.905% |
| vTv Therapeutics Inc. | 11.9 Million USD | -116.805% |
| Bio-Techne Corporation | 563.03 Million USD | 95.415% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | 93.685% |
| Harmony Biosciences Holdings, Inc. | 268.75 Million USD | 90.395% |
| Prelude Therapeutics Incorporated | 132.27 Million USD | 80.484% |
| Candel Therapeutics, Inc. | 14.41 Million USD | -79.134% |
| iTeos Therapeutics, Inc. | 163.69 Million USD | 84.23% |
| Nkarta, Inc. | 131.65 Million USD | 80.391% |
| BioCardia, Inc. | 12.12 Million USD | -112.977% |
| Iterum Therapeutics plc | 47.46 Million USD | 45.616% |